Past seminar

Timely access to new medicinal products


Wednesday 15 November 2017


Pakhuis de Zwijger
Piet Heinkade 179 (next to the Axon office)
1019HC Amsterdam

What time

Registration and coffee:


Start seminar:


Drinks and snacks:


Opportunities and challenges for the (bio) pharmaceutical industry

Improving the path from bench to bedside is the main goal of HollandBIO’s Faster, Better! Programme. This seminar covers an important aspect of the programme: providing patients timely access to new medicinal products. Next to PRIME (Priority Medicines) – alternative routes to the market do exist, such as named patient programmes, compassionate use and conditional marketing authorisations. Which early access tools suit your product best? Are new concepts such as adaptive pathways the way forward?

Obtaining early access to the market is one thing. However, reimbursement is vital to provide effective access for patients. An early dialogue with the stakeholders is crucial.

This seminar, which is organised in collaboration with HollandBIO, will provide a clear overview of alternative routes to the market. The speakers will elaborate on the opportunities and drawbacks.



Hanneke Later-Nijland

Attorney-at-law at Axon Lawyers

The legal framework: an overview and issues to consider

André Broekmans

Director at Lygature

Regulatory Innovation ADAPT SMART and reimbursement

Ingmar de Gooijer

Director Public Policy & Reimbursement at MyTomorrows

Do's and don'ts: advice from a disruptive market player

Anke Hövels

Assistant Professor Health Technology Assessment (HTA) at University of Utrecht

HTA decisions in view of timely access

Panel discussion

After the presentations, a panel of André Broekmans (Lygature), Tom Denee (Manager Market Access), Bart van der Lelie (Lysiac), Anke Hövels (University of Utrecht), and Ingmar de Gooijer (My Tomorrows) will share their specific viewpoints and discuss with the attendees.

Seminar Topic Suggestions

Do share your suggestions for a seminar topic with us by filling out the form below.
  • This field is for validation purposes and should be left unchanged.